Market Assessment
ContraVir Pharmaceuticals (CTRV) is a small-cap ($3.44M) clinical-stage biopharma developing innovative therapeutics for chronic liver diseases, hepatocellular carcinoma ((HCC)), viral liver diseases (HBV, HCV and HDV) and NASH, with high unmet medical needs. Its drug pipeline initially comprised TXL (formerly CMX157) and CRV431. On April 2019, Contravir terminated the 2014 license agreement with Chimerix (NASDAQ:CMRX) for the development and commercialization of CMX157 in viral infections including HBV.
Presently, CRV431 is its lead investigative drug candidate in clinical development for the treatment of chronic HBV infection and possibly NASH, the